Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

Crit Care. 2020 Aug 12;24(1):497. doi: 10.1186/s13054-020-03227-4.

Authors

Toru Hifumi¹, Shutaro Isokawa², Norio Otani², Shinichi Ishimatsu²

Affiliations

¹ Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. hifumitoru@gmail.com.
² Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.

No abstract available

Keywords: Adverse events; COVID-19; Favipiravir; Nafamostat mesylate.

Publication types

Letter
Comment

MeSH terms

Amides
Benzamidines
Betacoronavirus
COVID-19
Coronavirus Infections*
Critical Illness*
Guanidines
Humans
Pandemics*
Pneumonia, Viral*
Pyrazines
SARS-CoV-2

Substances

Amides
Benzamidines
Guanidines
Pyrazines
favipiravir
nafamostat